Article Versions Notes

Espinosa-Pereiro J, Ghimire S, Sturkenboom MGG, Alffenaar J-WC, Tavares M, Aguirre S, Battaglia A, Molinas G, Tórtola T, Akkerman OW, et al. Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial. Pharmaceutics. 2023; 15(1):9. https://doi.org/10.3390/pharmaceutics15010009

Espinosa-Pereiro, Juan, Samiksha Ghimire, Marieke G. G. Sturkenboom, Jan-Willem C. Alffenaar, Margarida Tavares, Sarita Aguirre, Arturo Battaglia, Gladys Molinas, Teresa Tórtola, Onno W. Akkerman, and et al. 2023. "Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial" Pharmaceutics 15, no. 1: 9. https://doi.org/10.3390/pharmaceutics15010009

Espinosa-Pereiro, J., Ghimire, S., Sturkenboom, M. G. G., Alffenaar, J.-W. C., Tavares, M., Aguirre, S., Battaglia, A., Molinas, G., Tórtola, T., Akkerman, O. W., Sanchez-Montalva, A., & Magis-Escurra, C. (2023). Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial. Pharmaceutics, 15(1), 9. https://doi.org/10.3390/pharmaceutics15010009